Sarah Rodrigue
Associate
Houston
sarah.rodrigue@lw.com
+1.713.546.7585
PRACTICES
- Capital Markets
- Mergers & Acquisitions
- Public Company Representation
INDUSTRIES
- Energy & Infrastructure
- Healthcare & Life Sciences
- Technology
EDUCATION
- JD, Vanderbilt University, 2020
- BS/BBA, University of Kentucky, 2017
magna cum laude
LANGUAGES SPOKEN
- English
PROFILE
Sarah Rodrigue is an associate in the Houston office of Latham & Watkins and a member of the firm’s Capital Markets Practice.
Sarah represents public and private companies, private equity firms, and their portfolio companies in a broad range of corporate and transactional matters, including public offerings and private placements of securities, high-yield and investment-grade debt offerings, tender offers, and both public and private mergers and acquisitions. Sarah also advises companies on general corporate and securities matters, including public reporting obligations.
She advises clients on a variety of corporate matters within a wide range of industries including energy, life sciences, biotechnology, telecommunications, and private equity.
Sarah maintains an active pro bono practice. She has represented individuals seeking asylum in the US, advised small businesses, and volunteered at legal clinics for displaced youth in Texas.
Prior to joining Latham, Sarah was an associate at another leading international law firm.
EXPERIENCE
Sarah’s experience includes advising:
- Olink Holding AB (publ) in its US$3.1 billion sale to Thermo Fisher Scientific*
- A NASDAQ-listed digital transformation solutions and services company in its sale to a European IT solutions company via tender offer, in addition to corporate governance matters*
- A NYSE-listed metal coating services company in its US$320 million underwritten public offering, in addition to corporate governance matters*
- Imunon Inc. in connection with numerous registered securities offerings, “at-the-market” securities offerings and other corporate governance matters*
- A privately-held transmission and distribution utility company in numerous 144A/Reg. S offerings of senior secured notes and the related A/B exchange offers*
- A NASDAQ-listed oncology drug development company in its successful uplisting to NASDAQ and various registered securities offerings of its shares of common and preferred stock, including a private investment in public equity (PIPE) offering*
- Sanofi in the sale of its generics business in Colombia, Peru, and Ecuador*
- A private equity fund group in the disposition of its portfolio companies*
- A South Korean textile maker and supplier on the acquisition of a US sportswear maker*
- A NYSE-listed distributor of motor fuel on the acquisition of European liquid fuels terminals*
- A multinational enterprise software company in the US$2.7 billion sale of its enterprise asset management division to an international industrial technology company*
- A global computer security software company on the US$4 billion divestiture of its enterprise business*
*Matter handled prior to joining Latham